Niraparib for the Treatment of Leiomyosarcoma

Summary

This phase II trial tests whether niraparib works to shrink tumor in patients with leiomyosarcoma. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Timeline

Start

2023-12-01

Primary completion

2024-12-31

Completion

2025-12-31

Drugs

Indications